Artificial Intelligence in Drug Discovery Market: Growth, Size, Share, and Trends

Report Code HIT 7445
Published in Nov, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Artificial Intelligence in Drug Discovery Market by Process (Target, Lead), Use Case (Design & Optimisation: Vaccine, Antibody; Disease understanding, PK/PD), Therapy (Cancer, CNS, CVS), Tool (ML:DL (CNN, GAN)), End User & Region - Global Forecast to 2029

Overview

The global AI in drug discovery market is expected to reach USD 6.89 billion by 2029 from USD 1.86 billion in 2024, at a CAGR of 29.9% during the forecast period. Standardization of diverse datasets generated from sources like clinical trials, genomics, and real-world evidence to efficiently exchange of information across various platforms & geographical regions, enhancing research collaboration between tech companies and pharmaceutical firms, emergence of technologies like AI, quantum computing, cognitive computing that harness large volumes of raw data into actionable insights, innovative solutions and targeted therapies, and leveraging diverse datasets like genetic, clinical, and chemical data to deliver insights, emphasize in the development for rare and orphan drugs, finding new drug candidates, etc., to reduce the workload on researchers & investigators are some of the prominent factors that contribute to the constantly increasing adoption of AI in drug discovery market.

Attractive Opportunities in the AI in Drug Discovery Market

North America

Well-established pharmaceutical industry, high focus on R&D, and the presence of leading pharmaceutical companies are boosting the market in North America.

The growth of this market is primarily driven by the growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, and the increasing focus on oncology indication.

Lack of suitable datasets to feed AI models, lack of access to proprietary databases, limited interoperability of existing datasets, lack of mature tools, and limited tool usability may hamper the growth of the market.

The European AI in drug discovery market is expected to be worth USD 1,965.9 million by 2029, growing at CAGR of 29.8% during the forecast period.

Increasing focus on precision medicine, growing biotechnology industry, and focus on developing human-aware AI systems, increasing adoption of AI-enabled single cell analysis offer several opportunities for market growth.

Global AI in Drug Discovery Market Dynamics

DRIVER: Growing cross-industry collaborations and partnerships

With the growing awareness of the benefits of AI and its application areas, the adoption of AI technology in drug discovery has increased.

Pharmaceutical and biotechnology companies are embracing AI on multiple fronts, from drug discovery and clinical development to safety monitoring and risk assessment. Major companies are entering into strategic collaborations and partnerships with the key players operating in the AI field. Such strategies enable these market players to offer highly sophisticated solutions, that is, AI-based drug discovery platforms, and ensure a more robust position in this volatile market space.

Companies in the AI drug discovery market are using both internal and external strategies to improve their drug development processes with cutting-edge technology. For example, in September 2023, Merck teamed up with BenevolentAI UK to take advantage of BenevolentAI's powerful AI platform and collaborate with a team of experts from various fields in drug discovery. Their goal is to identify promising candidates from the preclinical stage and begin developing innovative compounds. Similarly in September 2023, Intelligent OMICS Ltd and Janssen Research & Development, LLC ("Janssen") will co-develop Intellomx's proprietary AI platform combining multi-omics data merged with deep learning algorithms to identify novel mechanisms of disease and new therapeutic opportunities for treatment using Janssen research and development expertise in both data science and oncology. Owing to the growing demand for novel AI-based techniques in drug discovery, such developments are helping companies gain momentum in developing advanced AI-based products and tools. In January 2023, BioNTech completed the acquisition of InstaDeep for USD 440 milion. This acquisition will strengthen BioNTech position in the field of AI-powered drug discovery, design and development. Additionally, it will add ~290 highly skilled professionals to BioNTech, including experts in AI, machine learning, bioengineering, data science, and software development.

RESTRAINT: Shortage of AI workforce and ambiguous regulatory guidelines for medical software

AI is a sophisticated system that requires an employee with certain skill sets for developing, managing, and implementing it. For instance, the human resources operating with AI systems should be aware of other technologies like cognitive computing, ML and machine intelligence, deep learning, and image recognition. This is also a challenging process to integrate AI solutions with existing systems, which involve intricate processing of data to mimic the human brain activity. Even a small mistake can cause a system to fail or can adversely influence the desired outcome. The lack of professional standards and certifications in AI/ML technologies is hindering the growth of AI.

Moreover, it is intriguing for any government or regulatory agency to keep track with such fast developments and meaningfully guide the deployment of AI systems, particularly in healthcare applications. Before obtaining the approval of the FDA, AI or machine learning tools that are applicable to healthcare applications must pass tests to demonstrate that they can provide results at least as accurately as humans. For example, in Europe, software is not generally excluded; it can be assessed as a medical device if the purpose of this device is to perform a medical activity. Usually, case-by-case assessment is needed, taking into account the product characteristics, mode of use, and claims presented by the manufacturer. This assessment, however, is very complex because it is not clear from which general medical device classification, since software, unlike the abovementioned general medical devices, does not act on the human body to restore, correct, or modify such functions. Therefore, the use of software within healthcare settings is not necessarily a medical device. Such ambiguity in regulatory guidelines sometimes becomes a barrier for players.

 

OPPORTUNITY: Growing biotechnology industry

There is an ample amount of opportunities for making use of AI in drug discovery in the biotechnology industry. The private and public biotech companies total more than 2,000 in the United States, which has the largest concentration. As of 2023, IBISWorld reported 3,429 biotechnology businesses operating in the U.S. The biotech sector is becoming a leader in product and technology innovation and is essential for new product development across all biopharma companies.

Biopharmaceuticals are currently the fastest-growing segment of the pharmaceutical industry.. The reason is mainly because biopharmaceutical products are not only effective but also safe and can treat diseases that were not treatable in the past. With the growth in biotech companies, so does the overall investment in biotechnology research. This will result in larger and better-funded drug discovery efforts as this may hasten the development of new treatments. The biotechnology industry is booming and hence provides an excellent opportunity for the growth of the market for AI in drug discovery.

CHALLENGES: Computational limitations of advanced AI models

High-compute and high-storage requirements are significant for high-end AI models applied to drug discovery. This calls for significant infrastructure at a considerable cost. These models are huge data consumers and take very long training times, so most individual companies will find it impossible to obtain and train them adequately.

By financing to develop an AI infrastructure common to AI-driven drug discovery, which can be shared among various institutions, the government can overcome this problem. In this manner, advanced technologies can be availed of by other minor organizations without spending much in their systems. Besides that, through providing powerful computing resources, it may help these minor companies easily use complex AI techniques. The availability of innovative cutting-edge technology for everybody also promotes collaboration and sharing of data among the researchers themselves. Shared infrastructure investment in AI at last will help small companies get over technical barriers, bringing nearer personalized drug discovery medicine.

Global AI in Drug Discovery Market Ecosystem Analysis

The ecosystem of the AI in drug discovery market comprises investors, academic researchers/organizations, government and regulatory bodies, key players, startups, the drug discovery industry end users- pharmaceutical & biotechnology companies, contract research organizations, and research centers, academic institutes, & government organizations. The ecosystem also includes enablers such as data source providers, ERP providers, business intelligence and analytical tool providers, cloud service providers, web interface and application developers, network connectivity providers, security and privacy solutions providers, hardware providers, and consultants.

 

Pharmaceutical & biotechnology companies segment accounted for a substantial share of the AI in drug discovery market, by end user in 2023.

Pharmaceutical & biotechnology companies held the largest share of AI in the drug discovery market by end user in 2023. The significant share of this segment can be ascribed to growing demand for integration of AI and personalized medicine. The companies streamline their drug discovery processes to produce high-quality, safe products while also trying to save costs. Companies can collect and analyze all of their research data with the help of AI models to gain actionable insights in early drug discovery. Fast-track and increased precision predictions of new compounds' effectiveness and safety, which formerly took over a decade and billions of dollars in the laboratory. Consider Tempus (US) and Foundation Medicine, Inc., (US) companies developing platforms to improve cancer therapeutics and for rare disease management. They plan to provide efficient treatment of patients and minimize side effects. Together, these propel growth in the use of descriptive analytics, enabling innovation in the AI in drug discovery industry.

SAAS-based is expected to register highest growth in the AI in drug discovery market, by deployment

SaaS-based solutions are expected to register highest growth in the AI in drug discovery market the forecast period. Their growth will be mainly through increasing demand from companies in the field, which are adopting these solutions because of unlimited user support and on-demand access from anywhere, further increasing collaboration between researchers. To top this, these solutions require only a connection to the internet. This minimizes large upfront software license and hardware investments. Companies can subscribe to the extent of their needed usage. This arrangement is cloud-based, allowing online access to share and collaborate in real-time regarding experiments and improving communication between colleagues. For instance, in November 2023, Axtria introduced Axtria DataMAX Emerging Pharma, an AI-enabled SaaS solution designed for the commercialization and scaling of the operations of small and emerging biotech and pharmaceutical companies using data effectively.

North America dominated the AI in drug discovery market in 2023.

The AI in drug discovery market is studied for the five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The North American region dominated the AI in drug discovery market owing to factors such as the region's high per-capita healthcare expenditure, increased investment in healthcare technologies including AI, rising demand for personalized medicine driven by genomic data and patient-centric approaches, and the growing importance to reduce drug development costs & time, and focus for research on rare diseases. The growing focus on quality control, regulatory compliance, developed healthcare & drug discovery infrastructure, and the surging demand for digitalized technologies across North America further propels the growth. Moreover, the competitive landscape in North America encourages innovation among market players, driving continuous growth in technology and service offerings by various market vendors.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of AI in Drug Discovery Market

  • In September 2024, Insilico Medicine collaborated with Inimmune to leverage its proprietary AI platform, Chemistry42, in accelerating the discovery and development of next-generation immunotherapeutics.
  • In August 2024, Recursion and Exscientia plc announced an agreement, combining their technologies to enhance small molecule drug discovery. The integrated Recursion OS will enhance drug discovery through patient-centric target discovery, AI-driven design, quantum mechanics modeling, automated chemical synthesis, and more. The combined company plans to complete 10 clinical trials within 18 months. Exscientia shareholders will receive Recursion stock, with Recursion shareholders owning 74% of the combined company. The deal, worth USD 850 Million in cash, aims for USD 100 Million in annual synergies and is expected to close by early 2025
  • In June 2023, BenevolentAI collaborated with the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield on this program, utilizing its patient-derived motor neuron/iAstrocyte co-culture systems and in vivo model expertise.
  • In January 2023 Google collaborated with Bayer AG to drive early drug discovery that will apply Google Cloud’s Tensor Processing Units (TPUs) to help accelerate and scale Bayer’s quantum chemistry calculations.

Key Market Players

KEY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Artificial Intelligence in Drug Discovery Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Million/Billion (USD)
Segments covered Process, use case, therapeutic area, player type, AI tools, deployment, end user, and region
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

 

Key Questions Addressed by the Report

Which are the top industry players in the AI in drug discovery market?
The top market players in the global AI in drug discovery market include The artificial intelligence (AI) in drug discovery market is dominated by key players. The prominent players operating in this market are NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Valo Health (US), Merck KGaA (Germany), IQVIA (US), CytoReason (Israel) AbCellera (US), and others.
Which deployment models have been included in the AI in drug discovery market report?
This report contains the following components:
  • On-premise
  • Cloud-based
  • SaaS-based
Which geographical region dominates the global AI in drug discovery market?
The global AI in drug discovery market is further bifurcated into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America holds a substantial share, and registers the highest growth rate during the forecast period.
Which end users have been included in the AI in drug discovery market report?
The report contains the following industry segments:
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Centers, Academic Institutes, & Government Organizations
What is the total CAGR expected to be recorded for the AI in drug discovery market during 2024-2029?
The CAGR is expected to record a CAGR of 29.9% from 2024-2029.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Artificial Intelligence in Drug Discovery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
9
EXECUTIVE SUMMARY
25
PREMIUM INSIGHTS
37
MARKET OVERVIEW
56
  • 5.1 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.3 INDUSTRY TRENDS
    EVOLUTION OF AI IN DISCOVERY
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - AI IN DRY LAB
    - AI IN WET LAB
    COMPLEMENTARY TECHNOLOGY
    - HIGH-PERFORMANCE COMPUTING (HPC)
    - NEXT-GENERATION SEQUENCING
    - REAL-WORLD EVIDENCE/REAL-WORLD DATA
    ADJACENT TECHNOLOGIES
    - CLOUD COMPUTING
    - BLOCKCHAIN TECHNOLOGY
    - INTERNET OF THINGS (IOT)
  • 5.7 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY ANALYSIS
    - NORTH AMERICA
    - EUROPE
    - ASIA PACIFIC
    - LATIN AMERICA
    - MIDDLE EAST & AFRICA
  • 5.8 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS, BY PROCESS
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
  • 5.10 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR THE AI IN DRUG DISCOVERY MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.12 END-USER ANALYSIS
    UNMET NEEDS
    END-USER EXPECTATIONS
  • 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
  • 5.14 CASE STUDY ANALYSIS
  • 5.15 AI IN DRUG DISCOVERY MARKET: INVESTMENT AND FUNDING SCENARIO
  • 5.16 AI IN DRUG DISCOVERY MARKET: BUSINESS MODELS
  • 5.17 IMPACT OF AI/GEN AI IN THE AI IN DRUG DISCOVERY MARKET
AI IN DRUG DISCOVERY MARKET, BY PROCESS
68
  • 6.1 INTRODUCTION
  • 6.2 TARGET IDENTIFICATION & SELECTION
  • 6.3 TARGET VALIDATION
  • 6.4 HIT IDENTIFICATION & PRIORITIZATION
  • 6.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
  • 6.6 LEAD OPTIMIZATION
  • 6.7 CANDIDATE SELECTION AND VALIDATION
AI IN DRUG DISCOVERY MARKET, BY USE CASE
79
  • 7.1 INTRODUCTION
  • 7.2 UNDERSTANDING DISEASE
  • 7.3 DRUG REPURPOSING (INCLUDING DRUG PRIORITIZATION)
  • 7.4 DE NOVO DRUG DESIGN
    SMALL MOLECULE DESIGN
    VACCINES DESIGN
    ANTIBODY & OTHER BIOLOGICS DESIGN
  • 7.5 DRUG OPTIMIZATION
    SMALL MOLECULE OPTIMIZATION
    VACCINES OPTIMIZATION
    ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
  • 7.6 SAFETY AND TOXICITY
AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
91
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
  • 8.3 INFECTIOUS DISEASES
  • 8.4 NEUROLOGY
  • 8.5 METABOLIC DISEASES
  • 8.6 CARDIOVASCULAR DISEASES
  • 8.7 IMMUNOLOGY
  • 8.8 MENTAL HEALTH
  • 8.9 OTHERS (RESPIRATORY, NEPHROLOGY, DERMATOLOGY, GENETIC DISORDERS, GASTROINTESTINAL, AND RARE DISEASES)
AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE
106
  • 9.1 INTRODUCTION
  • 9.2 END-TO-END SOLUTION PROVIDERS (INCLUDING PLATFORM & SERVICE)
  • 9.3 NICHE/POINT SOLUTIONS PROVIDERS (INCLUDING PLATFORM & SERVICE)
  • 9.4 AI TECHNOLOGY PROVIDERS (ONLY SOFTWARE)
  • 9.5 BUSINESS PROCESS SERVICE PROVIDERS
AI IN DRUG DISCOVERY MARKET, BY TOOLS
126
  • 10.1 INTRODUCTION
  • 10.2 MACHINE LEARNING
    DEEP LEARNING
    - CONVOLUTIONAL NEURAL NETWORKS (CNN)
    - RECURRENT NEURAL NETWORKS (RNN)
    - GENERATIVE ADVERSARIAL NETWORKS (GAN)
    - GRAPH NEURAL NETWORKS (GNN)
    - OTHERS
    SUPERVISED LEARNING (SUPPORT VECTOR MACHINE, CLASSIFICATION & REGRESSION ALGORITHMS)
    REINFORCEMENT LEARNING (Q-LEARNING, DEEP Q-NETWORKS)
    UNSUPERVISED LEARNING (K-MEANS, DIMENSIONALITY REDUCTION)
    OTHER MACHINE LEARNING TECHNOLOGIES (SEMI-SUPERVISED LEARNING AND OTHERS)
  • 10.3 NATURAL LANGUAGE PROCESSING (NLP)
  • 10.4 CONTEXT-AWARE PROCESSING AND COMPUTING
  • 10.5 COMPUTER VISION
  • 10.6 IMAGE ANALYSIS (INCLUDING OPTICAL CHARACTER RECOGNITION)
AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT
154
  • 11.1 INTRODUCTION
  • 11.2 ON-PREMISE
  • 11.3 CLOUD-BASED
  • 11.4 SAAS-BASED
AI IN DRUG DISCOVERY MARKET, BY END-USER
165
  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS
  • 12.4 RESEARCH CENTERS, ACADEMIC INSTITUTES, & GOVERNMENT ORGANIZATIONS
AI IN DRUG DISCOVERY MARKET, BY REGION
187
  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 13.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    FRANCE
    UK
    ITALY
    SPAIN
    REST OF EUROPE
  • 13.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
198
  • 14.1 OVERVIEW
  • 14.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 14.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 14.4 MARKET SHARE ANALYSIS
  • 14.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.6 VALUATION AND FINANCIAL METRICS OF KEY AI IN DRUG DISCOVERY VENDORS
  • 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - PROCESS FOOTPRINT
    - USE CASE FOOTPRINT
    - THERAPEUTIC AREA FOOTPRINT
    - PLAYER TYPE FOOTPRINT
    - DEPLOYMENT FOOTPRINT
    - END-USER FOOTPRINT
  • 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 14.9 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    OTHERS
COMPANY PROFILES
206
  • 15.1 KEY PLAYERS
    NVIDIA CORPORATION
    EXSCIENTIA
    GOOGLE
    BENEVOLENTAI
    RECURSION
    INSILICO MEDICINE
    SCHRÖDINGER, INC.
    MICROSOFT CORPORATION
    ATOMWISE INC.
    ILLUMINA, INC.
    NUMEDII, INC.
    XTALPI INC.
    IKTOS
    TEMPUS LABS
    DEEP GENOMICS, INC.
    VERGE GENOMICS
    BPGBIO, INC.
    BENCHSCI
  • 15.2 VALO HEALTH
    INSITRO
VALO HEALTH
225
MERCK KGAA
  • 16.1 OTHER PLAYERS
    TENCENT
    PREDICTIVE ONCOLOGY, INC.
    IQVIA INC
    CYTOREASON
    OWKIN
    CLOUD PHARMACEUTICALS
    EVAXION BIOTECH
    STANDIGM
    BIOAGE LABS
    ENVISAGENICS
    ABCELLERA
    CENTELLA
APPENDIX
238
  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 17.3 AVAILABLE CUSTOMIZATIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

The study involved significant activities to estimate the current size of the artificial intelligence (AI) in drug discovery market. Exhaustive secondary research was done to collect information on artificial intelligence (AI) in drug discovery market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the artificial intelligence (AI) in drug doscovery market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in drug discovery solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of the Primary Respondents:

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2023: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the artificial intelligence (AI) in drug discovery market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the artificial intelligence (AI) in drug discovery market.

Market Definition

Artificial intelligence (AI) in drug discovery is the use of Al algorithms and techniques to improve the efficiency and effectiveness of the drug discovery process. Al can be used to automate tasks, analyze large datasets, and generate new insights that would be difficult or impossible to obtain using traditional methods. Al algorithms, particularly machine learning and deep learning models, are employed to analyze vast datasets on genetics, molecular structures, and biological interactions. These Al systems can predict potential drug candidates, assess their safety profiles, and optimize the drug development process.

AI in drug discovery enables faster target identification and in silico drug design. It identifies patterns in data to predict which compounds will be successful medicines. Al is still in the early stages of development in drug discovery, but it has the potential to revolutionize the process by automating tasks and analyzing large datasets. Al can create significant value in drug discovery through three main drivers: time and cost savings, increased probability of success, and novelty of both the molecular target and optimized therapeutic agent.

Stakeholders

  • AI Solution Providers
  • AI Platform Providers
  • Technology Providers
  • AI System Providers
  • Platform Providers
  • System Integrators
  • Pharmaceutical Companies
  • Biotechnology Companies and Start-ups
  • Drug Discovery Ventures
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Contract Research Organizations (CROs)
  • Research Centers and Universities
  • Academic Institutes
  • Forums, Alliances, and Associations
  • Distributors
  • Venture Capitalists
  • Government Organizations
  • Institutional Investors and Investment Banks
  • Investors/Shareholders
  • Consulting Companies in the Drug Discovery Sector and Regulatory Consultants
  • Raw Material and Component Manufacturers
  • Hardware Manufacturers and Suppliers
  • Data Providers
  • Regulatory Agencies
  • Healthcare Providers
  • Patient Advocacy Groups
  • Ethical and Legal Experts

Report Objectives

  • To define, describe, and forecast the global artificial intelligence (AI) in drug discovery market based on by process, use case, therapeutic area, player type, tools, deployment, end user, and region
  • To provide detailed information regarding the factors influencing the growth of the market (such as the drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall artificial intelligence (AI) in drug discovery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the artificial intelligence (AI) in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To provide key industry insights such as supply chain analysis, regulatory analysis, patent analysis, and impact of generative AI
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
  • To track and analyze competitive developments such as product & service launches; expansions; partnerships, agreements, and collaborations; and acquisitions in the artificial intelligence (AI) in drug discovery market
  • To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and R&D activities of the leading players in the market
  • To benchmark players within the artificial intelligence (AI) in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

Previous Versions of this Report

Artificial Intelligence in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028

Report Code HIT 7445
Published in Nov, 2024, By MarketsandMarkets™

Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028

Report Code HIT 7445
Published in Nov, 2023, By MarketsandMarkets™

Artificial Intelligence/AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts to 2027

Report Code HIT 7445
Published in Jun, 2022, By MarketsandMarkets™

Artificial Intelligence/AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts to 2027

Report Code HIT 7445
Published in Nov, 2019, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Artificial Intelligence in Drug Discovery Market

Anthony

Jun, 2022

Which market segment is expected to shape the future of the AI in Drug Discovery Market?.

Adam

Jun, 2022

Which are the most innovative companies in AI in Drug Discovery Market?.

Mathew

Jun, 2022

What are the new trends and advancements in the AI in Drug Discovery Market?.

DMCA.com Protection Status